Market potentials of ALK vaccination as a new strategy for the cure of ALK positive tumors such as lymphoma, lung carcinoma and neuroblastoma

Projektinformationen

ALKVAX

ID Finanzhilfevereinbarung: 324621

Projekt abgeschlossen

Startdatum 1 Juni 2013

Enddatum 31 Mai 2014

Finanziert unter

• Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 166 933,60

EU-Beitrag € 149 938,96

Koordiniert durch

UNIVERSITA DEGLI STUDI DI TORINO
Italy